Genedrive (GENE ), the near patient molecular diagnostics company, said it is included in a Public Health England ("PHE") national framework agreement for Diagnostics Goods and Services with all of its three CE-marked products to be included under the agreement.
The Group, which utilises its diagnostics platform to identify and treat infectious diseases and for other applications, informed investors this morning that the successful tender was made under Lot 1 of the National Microbiology Framework (Diagnostic Goods and Services).
The PHE tender was opened back in November 2020 and sought to appoint suppliers to a multi-lot national microbiology framework agreement relating to the supply of Diagnostics Goods and Services and covering Clinical Laboratory Diagnostic Testing Services.
While the framework is not exclusive to Genedrive, nor a guarantee of orders, the Group said it allows participating authorities ‘to issue call-off orders for products in the future.’
Shares in Genedrive have increased by over 50% in value since the beginning of 2021. The stock was trading 8.96% higher this morning at 73p following the announcement.
All of the Group’s currently available and CE marked products fall within the framework agreement and are to be included. This Company said this includes the Genedrive® 96 SARS-CoV-2 Kit, its Genedrive® HCV ID Kit as well as its Genedrive® MT-RNR1 ID Kit.
Commenting on the contract, David Budd, Chief Executive of Genedrive said: "We are very pleased to have received notice of this contract award decision and look forward to the opportunity to engage with PHE and relevant authorities on future potential contracts.”
He added, “This is an early notification of the decision and we will update shareholders when we have more information on what this contract may mean for orders and revenues".
Follow News & Updates from Genedrive here: